Caterina Pasquazzi | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Unexpected rise in the circulation of complex hbv variants enriched of hbsag vaccine-escape mutationshbvn HB genotype-d. Potential impact on hbsag detection/quantification and vaccination strategies	EMERGING MICROBES & INFECTIONS	2023
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C	LIVER INTERNATIONAL	2021
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b	VIRUSES	2021
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection	EMERGING MICROBES & INFECTIONS	2020
Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance	DIGESTIVE AND LIVER DISEASE	2019
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro	CLINICAL MICROBIOLOGY AND INFECTION	2019
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients	PLOS ONE	2018
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets	VIRUSES	2018
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis	INFECTION	2018
Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C Virus Genotypes 1-4 in Italy	SCIENTIFIC REPORTS	2018
Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy	DIGESTIVE AND LIVER DISEASE	2018
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?	JOURNAL OF HEPATOLOGY	2018
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies	LIVER INTERNATIONAL	2017
Ombitasvir/Paritaprevir/Ritonavir and dasabuvir combination treatment in patients with HIV/HCV co-infection: results of an italian compassionate use program	CLINICAL INFECTIOUS DISEASES	2017
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study	THE LANCET. GASTROENTEROLOGY & HEPATOLOGY	2017
Hepatitis Delta Antigen (HDAg) is characterized by an extensive degree of genetic variability that correlates with elevated levels of serum HDV-RNA	Journal of hepatologyJOURNAL OF HEPATOLOGY	2017
The circulation of specific vaccine-escape HBsAg mutations in HBV genotype D infected patients correlates with high viremia and affects HBsAg detection and quantification	JOURNAL OF HEPATOLOGY	2017
In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?	JOURNAL OF HEPATOLOGY	2017
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro	ONCOTARGET	2017
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens	PLOS ONE	2017